Successful Treatment of Papillomatosis Cutis Lymphostatica with Acitretin

Sir,
Papillomatosis cutis lymphostatica is a chronic hyperproliferative verrucous skin disorder, localized on lower legs or feet. It is caused by chronic lymphatic congestion and relapsing infections. We have recently treated a 53-year-old man suffering from this disorder with acitretin.

CASE REPORT
A 53-year-old man presented with a 12-year history of papillomatosis cutis lymphostatica complicated by ulceration. Chronic oedema due to venous insufficiency and venous thrombosis, lymphoedema and relapsing erysipelas had been present for many years. The medical history revealed long-standing obesity (body weight 160–200 kg). He suffered from hypertension, with right- and left-sided heart failure. His medication at the time consisted of captopril 25 mg bid and furosemide 80 mg once daily.

On examination, brownish grey discolouration, indurated skin areas, verrucous hyperkeratoses and desquamation were observed on both lower legs. At the preibial parts of the lower legs ulcerations were observed; these were surrounded by a fiercely red erythema and oozing because of lymph leakage. Both lower legs showed a non-pitting oedema. Peripheral arterial pulses were palpable. On physical examination we saw a severely overweight middle-aged man, not in acute distress, with a body weight of 190 kg and 176 cm height, and a blood pressure of 170/95 mm mercury. Laboratory examination – clinical chemistry, haematology and urinalysis – showed no abnormality apart from a creatinine of 120 micromol/l.

The treatment started with a dosage of 60 mg once daily. The patient was immobilized completely and compression of the legs commenced. Within 7 weeks the ulcers and the papillomatosis cutis had disappeared completely. A compressing hosiery (class 4) was used as maintenance treatment of the oedema. Acitretin was continued for 15 months. Four weeks after cessation of acitretin a new traumatically ulcer appeared on the left leg. It healed within 4 weeks. The papillomatosis cutis had not relapsed. Acitretin treatment was without side-effects.

DISCUSSION
The pathogenesis of papillomatosis cutis involves cutaneous inflammation, epidermal proliferation and abnormal keratinization (1–4). The lymphatic disorder which underlies the cutaneous response can be visualized and diagnosed with a non-directional lymphograph. Such an examination reveals pathologically widened lymphatics with valvular insufficiency (5).

The classical therapeutic approach consists of decongestion therapy, using compression bandages and/or a decompression pump. Superinfections are treated with antibiotics (6). Topical treatment with urea-containing keratolytics improves the hyperkeratotic aspect of the papillomatosis (7).

The present case demonstrates the remarkable therapeutic potential of acitretin for this condition. Within 2 months of treatment with acitretin, the severe expression of papillomatosis cutis lymphostatica with ulcerations remitted to a normal skin appearance. This excellent condition was maintained during 15 months’ maintenance treatment with acitretin. So far, i.e. 7 months after discontinuation of acitretin treatment, no relapse of the papillomatosis has been observed.

It is feasible that acitretin interferes with papillomatosis cutis lymphostatica by modulating proliferation and differentiation characteristics. Indeed, it has been well established that acitretin inhibits epidermal proliferation and terminal differentiation and modulates various aspects of cutaneous inflammation (8–10).

So far this communication is the first report on the therapeutic effect of acitretin in papillomatosis cutis lymphostatica. Further studies on patient groups are required to substantiate the position of acitretin as treatment for this condition.

REFERENCES

Accepted April 3, 1995.
A. Feind-Koelmans and P. C. M. van de Kerkhof.
Department of Dermatology, University Hospital Nijmegen, Nijmegen, The Netherlands.
Isotretinoin-induced Pemphigus

Sir,

A 17-year-old male patient came to us with vesicles, bullae and crusted erosions on his face, trunk, back, arms and legs. The patient also had lesions, typical of cystic acne, on his back.

Due to his cystic acne, the patient was treated initially with HCl-tetracycline and minocycline, but as he had no improvement, he started treatment with isotretinoin at a dosage of 1 mg/kg/day (a total of 90 mg/day was administered). Sixty days after the start of this treatment, blisters began to develop, first on his trunk and then on his face, arms, back and legs. The eruption was asymptomatic. After this we examined the patient. Examination revealed blisters and crusted erosions, widespread with no symptoms. Nikolsky sign was positive. The oral membrane showed no signs of the disease. The patient's general health was excellent.

A skin biopsy specimen showed intraepidermal bullae, severe acantholysis, suprabasal clefts with papillomatous projections of the dermis, typical of pemphigus (Fig. 1). Indirect immunofluorescence studies demonstrated circulating antibodies of IgG class, directed against the intercellular substance, at a titre of 1:160.

The diagnosis of drug-induced pemphigus was made and isotretinoin therapy was discontinued immediately, while treatment with prednisolone, at a dose of 75 mg/day, and azathioprine, at a dose of 200 mg/day, was started. Improvement of skin lesions was obvious within 3 weeks, with signs of healing, while complete recovery was achieved within 3 months.

The improvement of the antibody titre was also rather quick, it was negative about 6 months after the disease had started.

Prednisolone was discontinued gradually over a period of 7 months and azathioprine was administered to the patient, in total, for 9 months.

At a follow-up 52 months after the discontinuance of isotretinoin, the patient was still free of any sign of pemphigus and the antibody titre was negative.

A possible mechanism for the acantholysis in our case could be that retinoids may affect membranes, because of their lipophilic character (1). Our clues for the diagnosis of drug-induced pemphigus have been based on the following: a) the first signs of the bullous disease appeared a short period after the administration of the drug (isotretinoin); b) quick improvement (3rd week) and quick complete resolution (3rd month) of the disease, which is not very common in pemphigus; and c) despite the quick discontinuance of prednisolone and azathioprine, the patient has been free of clinical symptoms for almost 5 years and the titre of the antibodies still remains negative.

REFERENCES


Accepted March 14, 1995.

Sofia Georgala, M.D., University of Athens, Dimitrios Rigopoulos, M.D., Kalli Gourgiotou, M.D., Eleftheria Christofidou, M.D. “A. Sygros” Hospital, 5, I. Dragoumi, Athens, 116 21, Greece.

Fig. 1. Light microscopy of skin lesion (x160).
ANNOUNCEMENTS

British Society for Investigative Dermatology Meeting will be held in Glasgow, United Kingdom on March 28–29, 1996. For further information please contact Dr Graham Sharpe, Dept of Dermatology, University of Liverpool, PO. Box 147, Liverpool L69 3BX, UK. Tel: +44-151 706 4033. Fax: +44-151 706 5842.

The 23rd Annual Meeting of the Society for Cutaneous Ultrastructure Research will be held in Gardone Riviera, Brescia, Italy on April 11–13, 1996. For further information please contact Prof G. De Panfiliis, Department of Dermatology, Brescia University Hospital, I-25125 Brescia, Italy. Tel: +39-30 3995302/7. Fax: +39-30 3995015/6.

International Symposium on Pediatric Dermatology will be held in Rome, Italy on April 18–20, 1996. For further information please contact Professor Giuseppe Fabrizi, Department of Dermatology, Catholic University of Sacred Heart, largo Gemelli, 8, I-00168 Rome, Italy. Tel: and Fax: +39-6 3013250.

Fourth annual Summit on Cutaneous antifungal Therapy: Update on Management and New Therapy for the Clinician will be held in Vancouver, Canada on May 26–28, 1996. For further information please contact The Organizing Secretariat, CCT Healthcare Communication Limited, 50-52 Union Street, London Bridge, London SE1 1TD, UK. Tel: +44-171 407 9731. Fax: +44-171 403 5938.

Clinical Dermatology 2000 Vancouver will be held in Vancouver, Canada on May 28–31, 1996. For further information please contact The Organizing Secretariat, CCT Healthcare Communication Limited, 50-52 Union Street, London Bridge, London SE1 1TD, UK. Tel: +44-171 407 9731. Fax: +44-171 403 5938.

BOOKS RECEIVED


The first edition of “Patch testing” appeared in 1986 and contained a presentation of 2600 allergens with patch test concentrations, vehicles and references. This book has been a “must” for everybody engaged in patch testing during the past 10 years. Anton C. de Groot is also the co-author of another highly appreciated reference for patch testing: “Unwanted Effects of Cosmetics and Drugs used in Dermatology”, third edn, 1994, by Jan Willem Weyland, John Nater and Anton C. de Groot.

In this second edition of “Patch testing”, Anton C de Groot has updated his book to include detailed descriptions of test conditions and references for 3700 allergens. The layout of the text is still as comprehensive as in the first edition and as the content has been updated and includes references up to 1994, the book is strongly recommended to be used by everybody performing patch testing with more than the standard series.

Magnus Lindberg, MD, PhD
Department of Dermatology, University Hospital Uppsala, Sweden

ERRATUM


Table I is incorrect. The correct table is shown here.

Table I. Incidence and interval of melanocytes compared in previous and present studies

<table>
<thead>
<tr>
<th></th>
<th>Normal matrix (Higashi’s studies)</th>
<th>Matrix of PFK</th>
<th>Nail bed of PFK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval of melanocytes on vertical sections</td>
<td>77.3 to 170.5 μ (min. 25, max. 150)</td>
<td>90.7 μ (min. 25, max. 150)</td>
<td>112.5 μ (min. 75, max. 125)</td>
</tr>
<tr>
<td>Melanocyte incidence</td>
<td>First cell layer of epithelium</td>
<td>266±62 mm²</td>
<td>26±20 mm²</td>
</tr>
<tr>
<td></td>
<td>Four lower layers of epithelium</td>
<td>334±98 mm²</td>
<td>16±3 mm²</td>
</tr>
</tbody>
</table>

Acta Derm Venereol (Stockh) 75 © 1995 Scandinavian University Press. ISSN 0001-5555